Novo Nordisk ® s solid with 4% growth in a large ed value 2 is expected to grow by nually towards 2026 CAGR: +5% ILLUSTRATIVE Key trends in diabetes • Innovation focused on oral GLP-1 and combinations • Biosimilar competition and loss of exclusivity • Diabetes technology with digital health • Patients outcome beyond glucose control • Evolving payer dynamics and market access hurdles Insulin 2026 • Access and affordability of medicine ded in the insulin group; DPP-4i+SGLT2i products are included in the SGLT2i group); e compound annual growth rates (CAGR).
Download PDF file